	US 11,998,555 B2
	Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
Alfredo Grossi, Stoneham, MA (US); Britt Kostraba, Sandown, NH (US); Olatokumbo O. Luca Ogunleye, Tewksbury, MA (US); Shannon Terry, Somerville, MA (US); and Franciscus Koppenhagen, Salem, NH (US)
Assigned to scPharmaceuticals Inc., Burlington, MA (US)
Appl. No. 17/426,765
Filed by scPharmaceuticals Inc., Burlington, MA (US)
PCT Filed Jan. 30, 2020, PCT No. PCT/US2020/015799 § 371(c)(1), (2) Date Jul. 29, 2021, PCT Pub. No. WO2020/160210, PCT Pub. Date Aug. 6, 2020.
Claims priority of provisional application 62/799,215, filed on Jan. 31, 2019.
Prior Publication US 2022/0096500 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/635 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/32 (2006.01); A61M 5/142 (2006.01)

CPC A61K 31/635 (2013.01) [A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 47/32 (2013.01); A61M 5/14248 (2013.01)]

20 Claims

1. A liquid pharmaceutical formulation comprising:

(i) furosemide, or a pharmaceutically acceptable salt thereof;

(ii) benzyl alcohol, wherein the amount of benzyl alcohol in the liquid pharmaceutical formulation is from about 0.1% (w/w) to about 10% (w/w); and

(iii) a pharmaceutically acceptable buffer comprising tromethamine or a pharmaceutically acceptable salt thereof, wherein the concentration of tromethamine is from about 25 mM to about 100 mM,

wherein the concentration of furosemide in the liquid pharmaceutical formulation is greater than about 40 mg/mL and the pH of the liquid pharmaceutical formulation is from about 6.5 to about 8.5.